SelectQuote Gestion
Gestion contrôle des critères 3/4
Le PDG SelectQuote est Tim Danker, nommé en Jan2017, a un mandat de 9.42 ans. La rémunération annuelle totale est $ 3.49M, composée du salaire de 16% et des bonus 84%, y compris les actions et options de la société. détient directement 1.49% des actions de la société, d'une valeur de $ 2.25M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.7 ans et 5 ans.
Informations clés
Tim Danker
Directeur général
US$3.5m
Rémunération totale
| Pourcentage du salaire du PDG | 15.97% |
| Durée du mandat du directeur général | 9.4yrs |
| Propriété du PDG | 1.5% |
| Durée moyenne d'occupation des postes de direction | 4.7yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 06
SLQT: Earnings Outlook And Margin Improvement Will Support Future Upside Potential
Analysts have revised their SelectQuote price target to $5.00 to reflect updated assumptions, including a slightly lower revenue growth outlook, a modestly higher profit margin, and a revised discount rate and forward P/E that together indicate a more measured risk and valuation profile. What's in the News SelectQuote reaffirmed earnings guidance for Fiscal Year 2026, with revenue expected in a range of US$1.61b to US$1.71b.
Mise à jour du récit • May 21
SLQT: Local Franchise Rollout And FY26 Guidance Will Support Future P/E Re Rating
Analysts have adjusted their price target on SelectQuote to $1.25, with the change mainly tied to updated assumptions for the discount rate, revenue growth, profit margin, and future P/E rather than a shift in their overall fair value estimate. What's in the News SelectQuote reaffirmed its earnings guidance for Fiscal Year 2026, calling for revenue in a range of US$1.61b to US$1.71b (Key Developments).Mise à jour du récit • May 04
SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential
SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.Mise à jour du récit • Apr 20
SLQT: Local Franchise Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.
Mise à jour du récit • Apr 06
SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside
Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.Mise à jour du récit • Mar 22
SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.Mise à jour du récit • Mar 07
SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside
Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.Mise à jour du récit • Feb 21
SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside
Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.Mise à jour du récit • Feb 07
SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential
Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.Article d’analyse • Feb 06
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...Seeking Alpha • Feb 01
SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)
Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking AlphaMise à jour du récit • Jan 23
SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating
Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.Mise à jour du récit • Jan 09
SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating
Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.Mise à jour du récit • Dec 19
SLQT: Expanded Senior Support Services Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.Mise à jour du récit • Dec 05
SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.Mise à jour du récit • Nov 21
SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support
Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.Article d’analyse • Nov 15
Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding
The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...Mise à jour du récit • Nov 07
SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks
SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).Article d’analyse • Aug 31
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Article d’analyse • Jul 16
SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks
When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...Seeking Alpha • Apr 28
SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)
Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
Nouveau récit • Mar 26
Agent Efficiency And Medicare Services Will Transform 2025 Outlook
Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.Seeking Alpha • Feb 11
SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)
Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking AlphaArticle d’analyse • Jan 18
SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward
Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...Article d’analyse • Nov 20
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company
Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...Article d’analyse • Nov 07
SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50
It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...Article d’analyse • Oct 03
SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...Article d’analyse • Jul 02
SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares
When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...Article d’analyse • Feb 13
Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Seeking Alpha • Feb 07
SelectQuote Q2: Strong Revenue Growth But Retaining My Hold Rating
Summary SelectQuote, Inc.'s fiscal Q2 revenue of $405.44 million beat estimates, marking the 6th consecutive quarter of increasing YoY revenue. The company raised its revenue guidance for FY 2024 to $1.23 billion to $1.3 billion, a 17% increase from the prior low-end guidance. Despite positive revenue growth, SelectQuote is still losing money and has a significant long-term debt load of $650 million. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
SelectQuote: Insider Buying But A Significant Debt Load
Summary SelectQuote, Inc. is a small-cap online insurance broker with a stock that has had a huge decline since coming public in early 2020. However, the company has made some progress in reducing costs and the shares saw some significant insider purchases in May and September of this year. Time to buy into this improving story? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Nov 08
It's Probably Less Likely That SelectQuote, Inc.'s (NYSE:SLQT) CEO Will See A Huge Pay Rise This Year
Key Insights SelectQuote to hold its Annual General Meeting on 14th of November Total pay for CEO Tim Danker includes...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | n/a | n/a | US$20m |
| Sep 30 2025 | n/a | n/a | US$22m |
| Jun 30 2025 | US$3m | US$557k | US$25m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | n/a | n/a | -US$14m |
| Sep 30 2024 | n/a | n/a | -US$48m |
| Jun 30 2024 | US$3m | US$541k | -US$34m |
| Mar 31 2024 | n/a | n/a | -US$51m |
| Dec 31 2023 | n/a | n/a | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | US$3m | US$525k | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$115m |
| Dec 31 2022 | n/a | n/a | -US$132m |
| Sep 30 2022 | n/a | n/a | -US$292m |
| Jun 30 2022 | US$3m | US$525k | -US$298m |
| Mar 31 2022 | n/a | n/a | -US$193m |
| Dec 31 2021 | n/a | n/a | -US$151m |
| Sep 30 2021 | n/a | n/a | US$77m |
| Jun 30 2021 | US$3m | US$500k | US$125m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | n/a | n/a | US$129m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | US$4m | US$326k | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$25m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | n/a | n/a | US$40m |
| Jun 30 2019 | US$445k | US$305k | US$60m |
Rémunération vs marché: La rémunération totale de Tim ($USD 3.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.64M ).
Rémunération et revenus: La rémunération de Tim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Tim Danker (53 yo)
9.4yrs
Titularisation
US$3,487,527
Compensation
Mr. Timothy Robert Danker, also known as Tim, serves as Chief Executive Officer and Director at SelectQuote, Inc. since 2017. Mr. Danker served as the President of the SelectQuote’s Life Division from 2016...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 9.4yrs | US$3.49m | 1.49% $ 2.2m | |
| President | 4.7yrs | US$3.06m | 2.52% $ 3.8m | |
| Chief Financial Officer | 4.1yrs | US$2.17m | 0.18% $ 274.8k | |
| Chief Operating Officer | 7.4yrs | US$2.72m | 2.38% $ 3.6m | |
| General Counsel & Corporate Secretary | 6.7yrs | US$1.61m | 0.16% $ 246.9k | |
| Chief Accounting Officer | 5.8yrs | pas de données | 0.059% $ 89.1k | |
| Chief Communications & Investor Relations Officer | no data | pas de données | pas de données | |
| Chief Marketing Officer | 2.2yrs | pas de données | 0.071% $ 106.0k | |
| Chief Medical Officer & Member of Healthcare Advisory Board | 3.8yrs | pas de données | pas de données | |
| President of SelectQuote Senior | no data | pas de données | 0.35% $ 533.6k | |
| Executive Vice President of Healthcare Pharmacy Services | 1.9yrs | pas de données | 0.029% $ 44.0k |
4.7yrs
Durée moyenne de l'emploi
50yo
Âge moyen
Gestion expérimentée: L'équipe de direction de SLQT est considérée comme expérimentée (ancienneté moyenne 4.7 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | 9.4yrs | US$3.49m | 1.49% $ 2.2m | |
| Chief Medical Officer & Member of Healthcare Advisory Board | 4.3yrs | pas de données | pas de données | |
| Independent Chairman | 12.4yrs | US$225.00k | 0.29% $ 437.5k | |
| Independent Director | 12.4yrs | US$207.50k | 0.29% $ 437.5k | |
| Independent Director | 1.3yrs | US$150.33k | 0.0054% $ 8.1k | |
| Independent Director | 6.3yrs | US$245.00k | 0.21% $ 313.0k | |
| Independent Director | 1.3yrs | US$150.33k | 0.0054% $ 8.1k | |
| Independent Director | 6.3yrs | US$225.00k | 0.21% $ 309.6k | |
| Independent Director | 5.8yrs | US$215.00k | 0.21% $ 309.6k | |
| Member of Healthcare Advisory Board | 4.3yrs | pas de données | pas de données | |
| Member of Healthcare Advisory Board | 4.3yrs | pas de données | pas de données | |
| Member of Healthcare Advisory Board | 4.3yrs | pas de données | pas de données |
5.0yrs
Durée moyenne de l'emploi
53yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de SLQT sont considérés comme expérimentés (ancienneté moyenne 5 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/10 03:07 |
| Cours de l'action en fin de journée | 2026/06/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
SelectQuote, Inc. est couverte par 11 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Steven Valiquette | Barclays |
| Daniel Grosslight | Citigroup Inc |
| George Sutton | Craig-Hallum Capital Group LLC |